AU2001238124B2 - Adenosine a2a receptor antagonists for treating and preventing hepatic fibrosis,cirrhosis and fatty liver - Google Patents

Adenosine a2a receptor antagonists for treating and preventing hepatic fibrosis,cirrhosis and fatty liver Download PDF

Info

Publication number
AU2001238124B2
AU2001238124B2 AU2001238124A AU2001238124A AU2001238124B2 AU 2001238124 B2 AU2001238124 B2 AU 2001238124B2 AU 2001238124 A AU2001238124 A AU 2001238124A AU 2001238124 A AU2001238124 A AU 2001238124A AU 2001238124 B2 AU2001238124 B2 AU 2001238124B2
Authority
AU
Australia
Prior art keywords
adenosine
cirrhosis
receptor
fatty liver
hepatic fibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2001238124A
Other languages
English (en)
Other versions
AU2001238124A1 (en
Inventor
Edwin Chan
Bruce N Cronstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York University NYU
Original Assignee
New York University NYU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York University NYU filed Critical New York University NYU
Publication of AU2001238124A1 publication Critical patent/AU2001238124A1/en
Application granted granted Critical
Publication of AU2001238124B2 publication Critical patent/AU2001238124B2/en
Priority to AU2006203699A priority Critical patent/AU2006203699B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2001238124A 2000-02-10 2001-02-12 Adenosine a2a receptor antagonists for treating and preventing hepatic fibrosis,cirrhosis and fatty liver Ceased AU2001238124B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2006203699A AU2006203699B2 (en) 2000-02-10 2006-08-25 Adenosine A2A receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18154600P 2000-02-10 2000-02-10
US60/181,546 2000-02-10
PCT/US2001/004341 WO2001058241A2 (en) 2000-02-10 2001-02-12 Adenosine a2a receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2006203699A Division AU2006203699B2 (en) 2000-02-10 2006-08-25 Adenosine A2A receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver

Publications (2)

Publication Number Publication Date
AU2001238124A1 AU2001238124A1 (en) 2001-11-01
AU2001238124B2 true AU2001238124B2 (en) 2006-05-25

Family

ID=22664744

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001238124A Ceased AU2001238124B2 (en) 2000-02-10 2001-02-12 Adenosine a2a receptor antagonists for treating and preventing hepatic fibrosis,cirrhosis and fatty liver
AU3812401A Pending AU3812401A (en) 2000-02-10 2001-02-12 Adenosine a2a receptor antagonists for treating and preventing hepatic fibrosis,cirrhosis and fatty liver

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU3812401A Pending AU3812401A (en) 2000-02-10 2001-02-12 Adenosine a2a receptor antagonists for treating and preventing hepatic fibrosis,cirrhosis and fatty liver

Country Status (11)

Country Link
US (1) US6555545B2 (enExample)
EP (1) EP1272897B1 (enExample)
JP (1) JP2004502640A (enExample)
AT (1) ATE394104T1 (enExample)
AU (2) AU2001238124B2 (enExample)
CA (1) CA2398908C (enExample)
DE (1) DE60133887D1 (enExample)
DK (1) DK1272897T3 (enExample)
ES (1) ES2307593T3 (enExample)
PT (1) PT1272897E (enExample)
WO (1) WO2001058241A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6196459B1 (en) * 1998-05-11 2001-03-06 Ubiq Incorporated Smart card personalization in a multistation environment
WO2003080649A2 (en) * 2002-03-20 2003-10-02 Regents Of The University Of Minnesota Induction of hepatocyte proliferation in vitro by inhibition of cell cycle inhibitors
ITRM20070088A1 (it) * 2007-02-19 2008-08-20 Francesco Fringuelli Composti derivati della colchicina, procedimento per la loro preparazione e usi in campo medico.
CA2695989A1 (en) * 2007-08-10 2009-02-19 Glaxosmithkline Llc Certain nitrogen containing bicyclic chemical entities for treating viral infections
EP2217233B1 (en) * 2007-10-26 2018-08-08 New York University School of Medicine Methods and compositions for treating hepatic diseases
ES2541141T3 (es) * 2008-01-31 2015-07-16 Astellas Pharma Inc. Composición farmacéutica para el tratamiento de las enfermedades del hígado graso
WO2010040003A2 (en) * 2008-10-01 2010-04-08 The Scripps Research Institute Human a2a adenosine receptor crystals and uses thereof
US20100204265A1 (en) * 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
CA2755117C (en) 2009-03-13 2018-09-11 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
EP2408775B1 (en) * 2009-03-20 2015-06-17 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Oxidated derivatives of triazolylpurines useful as ligands of the adenosine a2a receptor and their use as medicaments
WO2011055391A1 (en) 2009-11-09 2011-05-12 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds, its preparation and uses thereof
HUE028640T2 (en) 2010-02-05 2016-12-28 Heptares Therapeutics Ltd 1,2,4-triazin-4-amine derivative
WO2012066330A1 (en) 2010-11-17 2012-05-24 Heptares Therapeutics Limited Compounds useful as a2a receptor inhibitors
KR20200022027A (ko) 2017-06-30 2020-03-02 리부 세라퓨틱스 에스.에이. 아데노신 A2A 수용체의 이미다조[1,2,a]피라진 조절물질
WO2019123482A1 (en) 2017-12-19 2019-06-27 Impetis Biosciences Ltd. Pharmaceutical composition for the treatment of cancer
SG11202006435XA (en) 2018-01-04 2020-08-28 Impetis Biosciences Ltd Tricyclic compounds, compositions and medicinal applications thereof
WO2020128036A1 (en) 2018-12-21 2020-06-25 Ryvu Therapeutics S.A. Modulators of the adenosine a2a receptor
WO2025018901A1 (en) 2023-07-17 2025-01-23 Ryvu Therapeutics S.A. Modulators of the adenosine a2a and a2b receptor

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4705658A (en) 1986-04-07 1987-11-10 Capsule Technology International, Ltd. Method for drying gelatin in the manufacture of hard shell gelatin capsules
US5063233A (en) 1986-11-14 1991-11-05 Ciba-Geigy Corporation N9 -cyclopentyl-substituted adenine derivatives useful as adenosine receptor agonists
US4968697A (en) 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
US5036381A (en) 1990-06-15 1991-07-30 Motorola, Inc. Multiple electronic devices within a single carrier structure
GB2264948B (en) 1992-03-13 1996-10-16 Merck & Co Inc Human adenosine receptors
US5426101A (en) 1992-09-30 1995-06-20 Merrell Dow Pharmaceuticals Inc. 2-substituted adenosines with A-2 receptor affinity
WO1994023723A1 (en) 1993-04-15 1994-10-27 New York University Adenosine receptor agonists for the promotion of wound healing
US5877180A (en) * 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
US5859019A (en) 1997-03-07 1999-01-12 Trustees Of The University Of Pennsylvania Methods for protecting against cardiac ischemia by administering adenosine A2a receptor antagonists
AU750322B2 (en) 1997-05-09 2002-07-18 Trustees Of The University Of Pennsylvania, The Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
AU7449598A (en) * 1997-05-23 1998-12-11 Nippon Shinyaku Co. Ltd. Medicinal composition for prevention or treatment of hepatopathy
US5916910A (en) 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
US6303619B1 (en) * 1998-03-12 2001-10-16 University Of Virginia Meta-substituted acidic 8-phenylxanthine antagonists of A3 human adenosine receptors
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response

Also Published As

Publication number Publication date
US20020002145A1 (en) 2002-01-03
DE60133887D1 (de) 2008-06-19
EP1272897B1 (en) 2008-05-07
AU3812401A (en) 2001-08-20
ATE394104T1 (de) 2008-05-15
DK1272897T3 (da) 2008-09-15
CA2398908C (en) 2009-12-15
WO2001058241A2 (en) 2001-08-16
PT1272897E (pt) 2008-08-18
CA2398908A1 (en) 2001-08-16
ES2307593T3 (es) 2008-12-01
JP2004502640A (ja) 2004-01-29
WO2001058241A9 (en) 2002-10-17
US6555545B2 (en) 2003-04-29
EP1272897A2 (en) 2003-01-08

Similar Documents

Publication Publication Date Title
AU2001238124B2 (en) Adenosine a2a receptor antagonists for treating and preventing hepatic fibrosis,cirrhosis and fatty liver
EP1365776B1 (en) Use of an adenosine a3 receptor agonist for inhibition of viral replication
EP1261322B1 (en) Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
AU2001238124A1 (en) Adenosine a2a receptor antagonists for treating and preventing hepatic fibrosis,cirrhosis and fatty liver
US20090253665A1 (en) Method of treatment of disease using an adenosine a1 receptor antagonist and an aldosterone inhibitor
WO2007149285A2 (en) Method of improved diuresis in individuals with impaired renal function
KR20080110776A (ko) 아데노신 ａ₁ 수용체 길항제 및 항경련제의 공동 투여
EP3380104B1 (en) An a3 adenosine receptor ligand for use in treating ectopic fat accumulation
US5069895A (en) Methods for the treatment of alcohol intoxication and dependence
ZA200509311B (en) Method of improved diuresis in individuals with impaired renal function
EP2217233B1 (en) Methods and compositions for treating hepatic diseases
AU2006203699B2 (en) Adenosine A2A receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver
US20200368223A1 (en) Methods for inhibiting phosphate transport
WO1995028177A1 (en) Medicinal composition for treating tardive dyskinesia and utilization thereof
US20210220300A1 (en) Methods of treating disease with dichlorphenamide
WO2002094317A1 (en) Methods and formulations of using a1 adenosine and p2x purinoreceptor antagonists
KR20250073663A (ko) Smarca2 분해제 및 kras 표적화 요법의 조합을 사용함으로써 개선된 암 치료
JP4194690B2 (ja) フェニルチアゾール骨格を有するプリンまたはピリミジンヌクレオシド取り込み阻害剤
HK1261991B (en) An a3 adenosine receptor ligand for use in treating ectopic fat accumulation
HK1261991A1 (en) An a3 adenosine receptor ligand for use in treating ectopic fat accumulation
EP1932529A1 (en) Method of improved diuresis in individuals with impaired renal function
IL156704A (en) Use of an adenosine a3 receptor agonist for the preparation of a pharmaceutical composition for inhibition of viral replication
HK1035670A1 (en) Antiviral combinations of lamivudine and adefovir

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired